Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, chronic lymphocytic (CLL)
Stage/Subtype:  stage 0 chronic lymphocytic leukemia
Trial Type:  Treatment
Results 1-12 of 12 for your search:
Start Over
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Lenalidomide and Combination Chemotherapy in Treating Patients with MYC-Associated B-Cell Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-1406, NCI-2014-01581, IRB13-1406, NCT02213913
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: eFT508-0002, NCI-2017-00209, NCT02937675
Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IPH2201-202, NCI-2017-00298, NCT02557516
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-0385, NCI-2009-01510, Celgene # RV-CLL-PI-0223, NCT00628238
Donor Umbilical Cord Blood Transplant After Combination Chemotherapy and Total-Body Irradiation in Treating Younger Patients With High-Risk Hematologic Malignancies
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: UCBT01, NCI-2011-03700, NCT01328496
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC138E, NCI-2014-02373, RV-CL-CLL-PI-003938, NCT02309515
Venetoclax and Ibrutinib in Treating Patients with Chronic or Small Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0860, NCI-2016-00797, NCT02756897
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Status: Active
Phase: Phase II
Type: Treatment
Age: 15 to 70
Trial IDs: 15-MMUD, NCI-2016-01455, NCT02793544
Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 69
Trial IDs: PCYC-1142-CA, NCI-2016-01487, NCT02910583
A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB 54828-203, NCI-2017-00141, NCT03011372
Ibrutinib in Treating Patients with Chronic Lymphocytic Leukemia
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0226, NCI-2016-01091, NCT02801578
Start Over